AU2018231664A1 - Usl-311 for use in the treatment of cancer - Google Patents

Usl-311 for use in the treatment of cancer Download PDF

Info

Publication number
AU2018231664A1
AU2018231664A1 AU2018231664A AU2018231664A AU2018231664A1 AU 2018231664 A1 AU2018231664 A1 AU 2018231664A1 AU 2018231664 A AU2018231664 A AU 2018231664A AU 2018231664 A AU2018231664 A AU 2018231664A AU 2018231664 A1 AU2018231664 A1 AU 2018231664A1
Authority
AU
Australia
Prior art keywords
cancer
sdf
fpkm
level
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018231664A
Other languages
English (en)
Inventor
Peter Richardson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proximagen LLC
Original Assignee
Proximagen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proximagen LLC filed Critical Proximagen LLC
Publication of AU2018231664A1 publication Critical patent/AU2018231664A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2018231664A 2017-03-10 2018-03-09 Usl-311 for use in the treatment of cancer Abandoned AU2018231664A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1703907.4 2017-03-10
GBGB1703907.4A GB201703907D0 (en) 2017-03-10 2017-03-10 Novel therapies for cancer
PCT/GB2018/050608 WO2018162924A1 (en) 2017-03-10 2018-03-09 Usl-311 for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
AU2018231664A1 true AU2018231664A1 (en) 2019-09-26

Family

ID=58605592

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018231664A Abandoned AU2018231664A1 (en) 2017-03-10 2018-03-09 Usl-311 for use in the treatment of cancer

Country Status (14)

Country Link
US (1) US20200281937A1 (cg-RX-API-DMAC7.html)
EP (1) EP3592356A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020514345A (cg-RX-API-DMAC7.html)
KR (1) KR20190128660A (cg-RX-API-DMAC7.html)
CN (1) CN110520130A (cg-RX-API-DMAC7.html)
AU (1) AU2018231664A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019018482A2 (cg-RX-API-DMAC7.html)
CA (1) CA3055470A1 (cg-RX-API-DMAC7.html)
EA (1) EA201992130A1 (cg-RX-API-DMAC7.html)
GB (1) GB201703907D0 (cg-RX-API-DMAC7.html)
IL (1) IL269121A (cg-RX-API-DMAC7.html)
MX (1) MX2019010679A (cg-RX-API-DMAC7.html)
SG (1) SG11201908166UA (cg-RX-API-DMAC7.html)
WO (1) WO2018162924A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
JP6927882B2 (ja) 2015-04-02 2021-09-01 プロキシマジェン,リミティド ライアビリティ カンパニー 癌の新治療法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201017345D0 (en) * 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
EP3030322A2 (en) * 2013-08-05 2016-06-15 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
JP6927882B2 (ja) * 2015-04-02 2021-09-01 プロキシマジェン,リミティド ライアビリティ カンパニー 癌の新治療法
GB201604213D0 (en) * 2016-03-11 2016-04-27 Proximagen Ltd Drug combination and its use in therapy

Also Published As

Publication number Publication date
MX2019010679A (es) 2020-02-05
JP2020514345A (ja) 2020-05-21
IL269121A (en) 2019-11-28
WO2018162924A1 (en) 2018-09-13
EP3592356A1 (en) 2020-01-15
CN110520130A (zh) 2019-11-29
GB201703907D0 (en) 2017-04-26
SG11201908166UA (en) 2019-10-30
BR112019018482A2 (pt) 2020-04-14
CA3055470A1 (en) 2018-09-13
US20200281937A1 (en) 2020-09-10
KR20190128660A (ko) 2019-11-18
EA201992130A1 (ru) 2020-02-04

Similar Documents

Publication Publication Date Title
US11369616B2 (en) Drug combination and its use in therapy
EP4031542B1 (en) Small molecule inhibitors of kras g12c mutant
CN111971279B (zh) 趋化因子受体调节剂及其用途
EP3216786B1 (en) Pyrimidine compounds, preparation method therefor and pharmaceutical uses thereof
TW202024071A (zh) 作為TAM及MET激酶抑制劑的吡唑并[3,4-b]吡啶化合物
WO2020027083A1 (ja) キナゾリン化合物を有効成分とする医薬組成物
EP3345906B1 (en) 2-arylamino pyridine, pyridine or triazine derivative, preparation method and use thereof
JP2022003080A (ja) 血小板由来成長因子受容体アルファの遺伝的異常に関連する癌の治療のための、1−[4−ブロモ−5−[1−エチル−7−(メチルアミノ)−2−オキソ−1,2−ジヒドロ−1,6−ナフチリジン−3−イル]−2−フルオロフェニル]−3−フェニルウレアおよびアナログの使用
WO2022199652A1 (en) Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof
RU2747645C2 (ru) Новые соединения
EP3122742A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
WO2021043208A1 (en) 3, 5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof
US20240409538A1 (en) Substituted triazoloheteroaryl compounds as usp1 inhibitors and the use thereof
JP2020531528A (ja) イミダゾリジン化合物
KR101480481B1 (ko) 퀴나졸린 화합물
WO2018162924A1 (en) Usl-311 for use in the treatment of cancer
CN119585256A (zh) 趋化因子受体调节剂及其用途
CN109640986A (zh) 用于治疗癌症的硫代乙内酰脲雄激素受体拮抗剂
CN114026097A (zh) 取代的吡唑并喹唑啉酮化合物及其应用
KR20180052631A (ko) 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도
WO2021047646A1 (en) Substituted imidazoquinoxaline compounds and uses thereof
TW202535865A (zh) 泛素特異性加工蛋白酶1 (usp1) 化合物
CN112480120A (zh) 取代的咪唑并喹喔啉化合物及其应用
HK40006480A (en) Inhibitors of bruton's tyrosine kinase

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period